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INTRODUCTION
Ovarian cancer is the most common gynecological
malignancy, with over 5,000 new cases diagnosed
every year in the UK and 22,000 in United States.
Malignant neoplasm of the ovaries occur at all ages
and the incidence rates increase dramatically with
age. Starting from women aged 40-44 years, which
has a rate of 15.7 per 100,000, and increased to a
rate of 54 per 100,000 in women 75-79 years old.
The rate increase to more than doubles after the
age of 50 years, while one third of the case was
found in women over 65 years old.1-6
The highest incidence was found in Norwegia
(15.3/100,000), while the lowest incidence was
found in Japan (3.2/100,000). In the Southeast Asia
region, including Indonesia, the incidence rate is
6.6%. Data from 2006-2008 in Department of Pa-
thology Medical Faculty University of Sriwijaya
Palembang demonstrated that ovarian cancer ac-
counts for 12% of all gynecological malignancy,
while in 2007 the incidence decereased until 7%
and in 2008, ovarian cancer accounts for 10% of
all gynecological malignancies.7,8
Abstract
Objective: To determine the effect of polymorphism of estrogen re-
ceptor β to the risk of epithelial ovarian carcinoma at Dr. Mohammad
Hoesin Hospital Palembang
Methods: This population-based case control study included 40
women with epithelial ovarian carcinoma and 40 controls, from
January 2010 until December 2011. Data analysis was performed by
Chi Square test.
Results: Distribution of estrogen receptor beta genotypes, both GT
and TT (wild type-mutant and mutant), among case subjects was
significantly higher than control (24 subjects {60%} vs. 5 subjects
{12.5%}). The genotype effect was statistically significant for
rs1271572 (OR=2.636; p=0.039) with Chi Square analysis. Whereas
the allotype effect was also statistically significant (OR=1.949; p=
0.047).
Conclusion: Polymorphism of estrogen receptor β may play a role in
the risk of epithelial ovarian carcinoma at Dr. Mohammad Hoesin
Hospital Palembang.
[Indones J Obstet Gynecol 2012; 36-1:32-6]
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Abstrak
Tujuan: Mengetahui adanya pengaruh polimorfisme rs1271572 gen
reseptor estrogen β pada kejadian karsinoma ovarium epitel di Rumah
Sakit Dr. Mohammad Hoesin Palembang.
Metode: Penelitian ini merupakan desain studi kasus control dengan
subjek 40 kasus dan 40 kontrol. Penelitian dimulai Januari 2010 sam-
pai Desember 2011. Analisis data menggunakan uji Chi Square.
Hasil: Dari hasil penelitian didapatkan distribusi genotip polimor-
fisme rs1271572 gen reseptor estrogen β ,di mana genotip GT dan TT
(wild type-mutan dan mutan) lebih banyak terdapat pada kelompok
kasus yaitu 24 kasus (60%) dan 5 kasus (12,5%), sedangkan pada
kelompok kontrol, yang terbanyak adalah genotip GG (wild type) de-
ngan 20 subjek (50%). Pengaruh polimorfisme gen reseptor estrogen
β pada kejadian karsinoma ovarium epitel berdasarkan genotipnya
dari analisis statistik dengan uji Chi Square, didapatkan nilai p=0,039
dan Odd Ratio 2,636. Sedangkan dari analisis statistik terhadap pe-
ngaruh polimorfisme reseptor estrogen β berdasarkan allotipenya di-
dapatkan nilai p=0,047 dan Odd Ratio=1,949.
Kesimpulan: Polimorfisme gen reseptor estrogen β mempengaruhi
terjadinya karsinoma ovarium epitel di Rumah Sakit Dr. Mohammad
Hoesin Palembang.
[Maj Obstet Ginekol Indones 2012; 36-1:32-6]
Kata Kunci: faktor risiko karsinoma ovarium, karsinoma ovarium
epitel, polimorfisme gen reseptor estrogen β
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Epithelial ovarian tumor consist of serous, muci-
nous, endometrioid, clear cell, and mixed epithelial
type. Epithelial type is the most common type found
in ovarian cancer, which accounts for 85%-90%.6-8
Based on the theory, etiology of ovarian cancer con-
sist of incessant ovulation hypothesis, gonadotropin
hypothesis, androgen hypothesis, progesteron hy-
pothesis, parity, pill contraception, tubal ligation,
menopausal hormonal replacemant therapy, and
hereditary factors. One of these that also affect the
incidence of ovarian cancer is involvement of estro-
gen receptor, both the alpha and beta receptor.
Thus, polymorphism of estrogen receptor gene may
play a role in the development of ovarian can-
cer.6,9,10
Endogenous and exogenous estrogen play a role
in ovarian carcinogenesis. Estrogen effects are me-
diated by two estrogen receptors, estrogen recep-
tor alpha (ERα) and estrogen receptor beta (ERβ).
Both ER subtypes are present in ovarian surface
epithelial cells, and reponsive to the estrogen. 9,10
Ovarian carcinoma is the most complex form of
all of malignancy, both hystopathologically and im-
muno hystochemically. Many researchers try to de-
termine the factors that may play a role in ovarian
carcinogenesis. One of those is polymorphism of es-
trogen receptor gene. Lurie et al (2008) demon-
strated the effect of polymorphism of estrogen re-
ceptor gene to the risk of epithelial ovarian cancer
and found that there is effect polymorphism of es-
trogen receptor β to the risk of epithelial ovarian
carcinoma.10,11
ERβ is the predominant type in the normal
ovary. It has been shown that it plays a role incellu-
lar proliferation and apoptosis. This polymorphism
of ERβ will altered the function of ERβ in cellular
regulation. A loss of ERβ expression could thus con-
stitute a crucial step in ovarian carcinogenesis, al-
though the precise mechanism of ERβ role in ovar-
ian carcinogenesis remains to be undetermined.5,6
Lurie et al found that there is an association be-
tween polymorphism of ERβ rs1271572 and the
risk of developing invasive ovarian carcinoma.10-12
That, combined with the fact that there is no pre-
vious finding about polymorphism of ERβ in Dr.
Mohammad Hoesin Hospital Palembang, caused
the researcher to be interested in this finding.
METHODS
This study was a case control study, held in Obstet-
rics and Gynecology Department at Dr. Mohammad
Hoesin Hospital, Palembang, in collaboration with
Palembang Distric Laboratory, South Sumatera, In-
donesia, from January 2010 until December 2011.
Subject of this study was women diagnosed with
epithelial ovarian carcinoma admitted to the ob-
stetric and gynecology ward in Dr. Mohammad
Hoesin hospital, Palembang.
Inclusion criterias were women diagnosed with
epithelial ovarian carcinoma, proven by histopatol-
ogy examination, agree for blood examination and
signing the informed consent form. The control
group consists of patients diagnosed with no neo-
plasm, who were willing to be the subject of the
study and signing the informed consent form.
Patient meeting the inclusion criteria received
counseling and a questionnaire. The blood sample
was taken and placed in reaction glass which was
already filled with 3 cc ethylene diamine tetraacetic
(EDTA). Then, the glass was placed at maximum
temperature 40° Celcius until the PCR was done,
followed by DNA extraction.
To determine the polymorphism of estrogen re-
ceptor β, the allele was analyzed with PCR method
followed with sequencing. This study determined
the polymorphism of estrogen β gene receptor at
5’ region (rs1271572) using a pair of primary nu-
cleotide forward TGCCAGCGACACACTCT and re-
verse AGGCCTTTCGCGTTAGATCA resulting 700
bp. Amplification with PCR method was done at
thermal cycle DNA branded ICycler BIO-RAD Labo-
ratories GB programmed for two step cycle based
on modified Yaich method at a temperature of 95°
Celcius denaturation for 5 minutes, followed by 30
cycles of denaturation at a temperature of 94° Cel-
cius for 60 seconds, annealing at a temperature of
66° Celcius for 60 seconds and extension at a tem-
perature of 72° Celcius for 60 seconds. Recently
performed final extension cycle for 6 minutes at a
temperature of 72° Celcius.
DNA sequencing was performed to confirm the
presence of allele polymorphism. DNA sequencing
was performed in the laboratory of molecular bi-
ology Eijkman Jakarta. All data were analyzed us-
ing SPSS 16.0 for Windows.
RESULT
From January 2010 until December 2011, we had
80 subjects, divided into 40 subjects as case group
and 40 subjects as control. Age was divided into 2
groups based on the value of mean 43.13±10.74
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(43 years). We found that 67.5% of the subjects in
the cases group are in ≥ 43 year age range. Largest
proportion of parity in the case is nulliparous of
37.5%. History of hormonal contraceptive use in
the case of 40.0% where as in the control group
by 52.5%. There is 62.5% subjects with meno-
pausal status at the case group which is the largest
percentage, while there were 55.0% subject in the
control group not menopause yet. In the case
group, found that 2.5% of the subjects had a family
history of ovarian cancer while in the control group
it was 10% of the subject.
To assess the polymorphism of β estrogen recep-
tor, alleles analyzed by PCR (Polymerase Chain Re-
action) and followed by DNA sequencing to confirm
the presence of allele polymorphism. From the DNA
sequencing, individuals with no polymorphisms in
β estrogen receptor gene showed with wild-type al-
lele with GG genotype. The existence of polymor-
phisms in β estrogen receptor gene is indicated by
changes in G to T. Subject who have a homozygous
mutant allele with the TT genotype while in indi-
viduals with wild-type and mutant alleles (het-
erozygous) with GT genotype. At electroperogram
of DNA sequencing, interpretation is peaks consist
of four colors representing each nucleotide that is
green for adenine (A), red for thymine (T), blue for
cytosine (C), and black for guanine (G).
There were 60% subject at case group with GT
genotype while there were 45% at the control
group. Case group had 12.5% with TT genotype
while control group had 5% of it.
Table 1. Distribution of genotype polymorphism
rs1271572 at 5’area receptor β estrogen gene
Genotype polymorphism
rs1271572
at 5’ area
Group
Case % Control %
GG (Wild type) 11  27.5 20  50.0
GT (Wild type/mutant) 24  60.0 18  45.0
TT (Mutant)  5  12.5  2   5.0
Total 40 100.0 40 100.0
Statistical analysis Chi Square test found a sig-
nificant effect of genotype polymorphism rs1271572
in the area of 5’ estrogen receptor β gene on the
incidence of epithelial ovarian carcinomas (p=0.039)
with the odds ratio of 2.63.
Table 2. Effect of genotype polymorphism rs1271572 on 5’
area estrogen receptor β gene to the incidence of epithelial
ovarian carcinomas.
Genotype polymorphism
rs1271572
on 5’ area
Group
Case % Control %
TT + GT 29  72.5 20  50.0
GG 11  27.5 20  50.0
Total 40 100.0 40 100.0
Chi Square test, p = 0.039; OR = 2.636; 95% CI (1.04-6.68)
T allotype (mutant) is higher in case group
(42.5%) while in control group (27.5%).
Table 3. The effect of allotype polymorphism rs1271572 in
5’ area estrogen receptor β gene to the incidence of epithel-
ial ovarian carcinoma.
Allotype polymorphism
rs1271572
in 5’ area
Group
Case % Control %
T (Mutant) 34  42.5 22  27.5
G (Wild type) 46  57.5 58  72.5
Total 80 100.0 80 100.0
Chi Square test, p = 0.047; OR = 1.949; 95% CI (1.01-3.77)
There are 16 subjects in case group who use
hormonal contraceptive and there are 21 subjects
in control group. From 16 subjects in case group,
majority of women has T allotype, it’s about 46.9%
while G allotype is 71.4% found in control group.
Table 4. The effect of allotype polymorphism rs1271572
estrogen receptor β gene in 5’ area to the incidence of epi-
thelial ovarian carcinoma based on hormonal contraceptive
use
Allotype polymorphism
rs1271572
in 5’ area
Group
Case % Control %
T (Mutant) 15  46.9 12  28.6
G (Wild type) 17  53.1 30  71.4
Total 32 100.0 42 100.0
Chi Square test, p = 0.105; OR = 2.206; 95% CI (0.84-5.78)
(b) GT on case 6
Figure 1. DNA sequencing.
(c) TT on case 10(a) GG on case 2
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DISCUSSION
The incidence rate of epithelial ovarian carcinoma
increase dramatically with age. The age group 40-
44 years, which has a rate of 15.7 cases per
100,000, and the rate more than doubles after the
age of 50 yeras to about 35 cases per 100,000.
The case subjects in this finding, majority of
women is nulliparous. McGowan et al reported in
his study that 197 women with ovarian cancer
found the nulliparous had a 2.45 times increased
risk of malignant ovarian tumor compared with the
parous women (with parity 3 or more).
Based on histrory of hormonal contraceptive
use, percentage of contraceptive use is higher in
control group, it’s about 21 subjects (52%) than
case group, it’s about 16 subjects (40%). Many of
studies report that pill contraceptive use can de-
crease risk of ovarian carcinoma.
Majority of case subjects in this researchis post-
menopausal women, it’s about 25 subjects (62.5%)
Based on the theory more than 80% epithelial
ovarian carcinoma is found in postmenopause.
While in premenopausal women, malignant ovar-
ian tumor is found only 7%. Based on the theory,
menopause itself did’nt affect ovarian cancer, but
the study report that there is association between
use of hormonal replacement therapy during
menopause in long period (more than 10 years)
with the increase of ovarian cancer risk. Although
in this study, all of menopausal subjects, there is
no subject who use hormonal replacement therapy.
History of familial ovarian carcinoma is found only
2.5% in case group, while the higher percentage is
10% found in control group. The majority of he-
reditary ovarian cancer is caused by mutation of
BRCA1 and BRCA2 genes, also in breast cancer.
Result of allele analysis with PCR method (Po-
lymerase Chain Reaction) followed with DNA se-
quence, found polymorphism of estrogen receptor
β rs1271572 which is shown there is transition al-
lele GT. Where as the reference of nucleotide se-
quence is taken based on data from National Cen-
ter for Biotechnology Information(NCBI) for SNPs
rs1271572: TTAGGCACAGATGTGACACTGGGGGG[G/T]
TCTCACAATGGCCTGTGGGTCACAT. From this sequence
found three genotype such as GG (wild type), GT (wild
type-mutant), and TT (mutant).
Based on the genotype distribution from the re-
sult of allele analysis through DNA sequence found
60% subjects in case group with GT genotype,
while control group is 45%. For TT genotype, there
is 12.5% in epithelial ovarian carcinoma group and
5% in control group. While the control group has
higher proportion for GG genotype (wild type).
In epithelial ovarian carcinoma group found that
there is significantly differentiation in percentage
between GT and TT (wild type-mutant and mutant)
compared to GG (wild type), it’s about 72.5% for
genotype polymorphism, while only 27.5% for nor-
mal genotype. From the result of Chi Square test
statistically found that there is effect of genotype
polymorphism ERβ rs1271572 significantly to the
risk of epithelial ovarian carcinoma with p value =
0.039 and OR=2.636. Result of analysis statistically
based on allotype to determine the effect to the risk
of epithelial ovarian carcinoma that also show the
significantly result with p value = 0.047 dan OR =
1.949.
The effect of rs1271572 polymorphism suggest
the result of previous finding which also suggest the
similar result. From 10 case control studies found
that there is association TT genotype rs1271572
with risk of ovarian cancer. Estrogen receptor β is
the predominant type in the normal ovary. Estrogen
interact with their receptors to mediate various sig-
naling pathways and biologic activity of estrogen
play a role to affect the growth and cell differentia-
tion as well as function of reproductive tissue. The
role of estrogen receptor β itself is in regulation of
cancer cells that play a role of regulation cellular
proliferation (antiproliferative), cell motility, and as
cell apoptosis. However, with there is this polymor-
phism may alter the role of regulation in cellular
proliferation which will affect transcription process
become abnormal and then as antiapoptotic cell.
Based on hormonal contraceptive use, the effect
of allotype polymorphism rs1271572 itself to the
risk of epithelial ovarian carcinoma found statistic
analysis with Chi Square test show that there is no
effect significantly with p value=0,105. In the study
by Lurie et al found there is association between
polymorphism rs1271572 to the risk of ovarian
cancer in women who never use hormonal contra-
ceptive with p value = 0.04.
CONCLUSION
In this study found there is significantly effect be-
tween polymorphism rs1271572 in 5’ region estro-
gen receptor β to the incidence of epithelial ovarian
cancer (p=0.039).
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